asthma

News

EU regulators accept Novartis' triple asthma combo

European regulators have accepted Novartis’ filing for a triple combination therapy for asthma known as QVM149, triggering payments to development partners Vectura and Sosei.

News

Sanofi claims EU okay for Dupixent in asthma

Sanofi and partner Regeneron have picked up an approval in Europe for Dupixent in asthma, unlocking an important new indication for the fast-growing biologic.

News

Trial could unlock asthma use for GSK’s Trelegy

GlaxoSmithKline CEO Emma Walmsley has been predicting big things for respiratory triple therapy Trelegy in the next couple of years and has new data that could open up a new market.

News

AZ's Fasenra also works in rare organ damage diseases

AstraZeneca’s asthma drug Fasenra also works in a group of rare diseases that can lead to potentially fatal organ damage, a mid-stage trial has shown.

News

Mylan launches Advair generic at 70% discount in US

Mylan has launched its generic version of GlaxoSmithKline’s respiratory blockbuster, Advair, at a 70% discount compared with the original drug.

News

NICE broadens approval for AstraZeneca’s severe asthma drug

AstraZeneca’s Fasenra (benralizumab) has seen its fortunes reverse after NICE approved the drug for severe eosinophilic asthma – broadening its recommendations for the drug’s use and giving

EU regulators accept Novartis' triple asthma combo

Sanofi claims EU okay for Dupixent in asthma

Trial could unlock asthma use for GSK’s Trelegy

AZ's Fasenra also works in rare organ damage diseases

Mylan launches Advair generic at 70% discount in US

NICE broadens approval for AstraZeneca’s severe asthma drug

Rethinking clinical research: The case for human challenge t...

Discover a new era of healthcare panel engagement: Grounded ...

asthma

Editor's Picks